Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models

Molecular Oncology

Volumn 3, Issue 5-6, 2009, Pages 469-482

  Bergamaschi, Anna ^a   Hjortland, Geir Olav ^a   Triulzi, Tiziana ^b   Sørlie, Therese ^a,c   Johnsen, Hilde ^a   Ree, Anne Hansen ^a,d   Russnes, Hege Giercksky ^a   Tronnes, Sigurd ^d   Mælandsmo, Gunhild M ^a   Fodstad, Oystein ^a   Borresen Dale, Anne Lise ^a   Engebraaten, Olav ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF OSLO   (Norway)

^d AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

Basal; Breast cancer; Genome array; Luminal; Model system; RNA microarray

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR ALPHA; MATRIGEL; SCLEROPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INVASION; CANCER MODEL; CANCER PATIENT; CANCER TRANSPLANTATION; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IN VIVO STUDY; INTRADUCTAL CARCINOMA; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE; TUMOR GENE; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALIA; MUS;

EID: 70350571374     PISSN: 15747891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molonc.2009.07.003     Document Type: Article

References (23)

1. Bergamaschi A., Kim Y.H., Wang P., Sorlie T., Hernandez-Boussard T., Lonning P.E., Tibshirani R., Borresen-Dale A.L., and Pollack J.R. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer 45 11 (2006) 1033-1040
2. Bergamaschi A., Tagliabue E., Sorlie T., Naume B., Triulzi T., Orlandi R., Russnes H.G., Nesland J.M., Tammi R., Auvinen P., et al. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J. Pathol. 214 3 (2008) 357-367
3. Bhowmick N.A., Neilson E.G., and Moses H.L. Stromal fibroblasts in cancer initiation and progression. Nature 432 7015 (2004) 332-337
4. Church G.M., and Gilbert W. Genomic sequencing. Proc. Natl. Acad. Sci. U.S.A. 81 7 (1984) 1991-1995
5. Dowsett M., Houghton J., Iden C., Salter J., Farndon J., A'Hern R., Sainsbury R., and Baum M. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann. Oncol. 17 5 (2006) 818-826
6. Geisler S., Lonning P.E., Aas T., Johnsen H., Fluge O., Haugen D.F., Lillehaug J.R., Akslen L.A., and Borresen-Dale A.L. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res. 61 6 (2001) 2505-2512
7. Hayes D.F., Thor A.D., Dressler L.G., Weaver D., Edgerton S., Cowan D., Broadwater G., Goldstein L.J., Martino S., Ingle J.N., et al. HER2 and response to paclitaxel in node-positive breast cancer. N. Engl. J. Med. 357 15 (2007) 1496-1506
8. Hennessy B.T., Gonzalez-Angulo A.M., Stemke-Hale K., Gilcrease M.Z., Krishnamurthy S., Lee J.S., Fridlyand J., Sahin A., Agarwal R., Joy C., et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 69 10 (2009) 4116-4124
9. Lingjaerde O.C., Baumbusch L.O., Liestol K., Glad I.K., and Borresen-Dale A.L. CGH-Explorer: a program for analysis of array-CGH data. Bioinformatics 21 6 (2005) 821-822
10. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25 4 (2001) 402-408
11. Luo M., Fan H., Nagy T., Wei H., Wang C., Liu S., Wicha M.S., and Guan J.L. Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells. Cancer Res. 69 2 (2009) 466-474
12. Marangoni E., Vincent-Salomon A., Auger N., Degeorges A., Assayag F., de Cremoux P., de Plater L., Guyader C., De Pinieux G., Judde J.G., et al. A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin. Cancer Res. 13 13 (2007) 3989-3998
13. Massarweh S., and Schiff R. Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities. Clin. Cancer Res. 13 7 (2007) 1950-1954
14. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., Gianni L., Baselga J., Bell R., Jackisch C., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353 16 (2005) 1659-1672
15. Rakha E.A., and Ellis I.O. Triple-negative/basal-like breast cancer: review. Pathology 41 1 (2009) 40-47
16. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer Jr. C.E., Davidson N.E., Tan-Chiu E., Martino S., Paik S., Kaufman P.A., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353 16 (2005) 1673-1684
17. Schneider B.P., Winer E.P., Foulkes W.D., Garber J., Perou C.M., Richardson A., Sledge G.W., and Carey L.A. Triple-negative breast cancer: risk factors to potential targets. Clin. Cancer Res. 14 24 (2008) 8010-8018
18. Sorlie T., Wang Y., Xiao C., Johnsen H., Naume B., Samaha R.R., and Borresen-Dale A.L. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics 7 (2006) 127
19. Sorlie T., Tibshirani R., Parker J., Hastie T., Marron J.S., Nobel A., Deng S., Johnsen H., Pesich R., Geisler S., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. U.S.A 100 14 (2003) 8418-8423
20. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., van de Rijn M., Jeffrey S.S., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U.S.A 98 19 (2001) 10869-10874
21. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U.S.A 102 43 (2005) 15545-15550
22. Tusher V.G., Tibshirani R., and Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. U.S.A 98 9 (2001) 5116-5121
23. Winer E.P., Berry D.A., Woolf S., Duggan D., Kornblith A., Harris L.N., Michaelson R.A., Kirshner J.A., Fleming G.F., Perry M.C., et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J. Clin. Oncol. 22 11 (2004) 2061-2068